West Pharmaceutical Services, Inc.
NYSE-WST
Company Overview
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Name
West Pharmaceutical Services, Inc.
CEO
Mr. Eric M. Green
Website
www.westpharma.com
Sector
Life Sciences Tools and Services
Year Founded
1923
Profile
Market Cap
$22.17B
EV
$22.03B
Shares Out
72.54M
Revenue
$2,876.9M
Employees
10,600
Margins
Gross
35.68%
EBITDA
26.31%
Operating
21.23%
Pre-Tax
21.8%
Net
18.25%
FCF
12.41%
Returns (5Yr Avg)
ROA
16.33%
ROTA
23.51%
ROE
23.23%
ROCE
23.59%
ROIC
23.76%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$351.85
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$446.2M
Net Debt
-$132.2M
Debt/Equity
0.12
EBIT/Interest
84.82
Growth (CAGR)
Rev 3Yr
4.48%
Rev 5Yr
10.23%
Rev 10Yr
7.47%
Dil EPS 3Yr
0.93%
Dil EPS 5Yr
18.44%
Dil EPS 10Yr
16.09%
Rev Fwd 2Yr
2.33%
EBITDA Fwd 2Yr
1.96%
EPS Fwd 2Yr
-2.61%
EPS LT Growth Est
6.32%
Dividends
Yield
—
Payout
11.1%
DPS
$0.79
DPS Growth 3Yr
5.65%
DPS Growth 5Yr
6.01%
DPS Growth 10Yr
7.18%
DPS Growth Fwd 2Yr
6.03%